Osteonecrosis of the jaw and the role of macrophages

Journal of the National Cancer Institute

Volumn 103, Issue 3, 2011, Pages 232-240

  Pazianas, Michael ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; COLONY STIMULATING FACTOR 1; DENOSUMAB; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; SODIUM FLUORIDE F 18; SUNITINIB; ZOLEDRONIC ACID;

BONE BLOOD FLOW; BONE CELL; BONE NECROSIS; CLINICAL FEATURE; DRUG EFFICACY; HISTOLOGY; HUMAN; JAW OSTEONECROSIS; MACROPHAGE; MOUTH INFECTION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ALENDRONATE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIDAZOLES; INDOLES; JAW DISEASES; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MEVALONIC ACID; MONOCYTES; MOUTH MUCOSA; OSTEOCLASTS; OSTEOMYELITIS; OSTEONECROSIS; POSITRON-EMISSION TOMOGRAPHY; PYRROLES; RADIOGRAPHY, PANORAMIC; RANK LIGAND; RISK FACTORS; SIGNAL TRANSDUCTION; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D;

EID: 79551716260     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq516     Document Type: Review

References (92)

1. Editor's note: Phosphorus necrosis under control. B Dent J. 1944;76:343.
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-1117. (Pubitemid 37064711)
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527-534. (Pubitemid 38542516)
4. Treister NS, Sook-Bin Woo. Bisphosphonate-associated osteonecrosis of the jaws. In: Rosen CJ, Compston JE, Lian JB, eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th ed, Chapter 107. Hoboken, NJ: John Wiley & Sons, Inc; 2009:505-509.
5. Coleman RE, Woodward EJ, Brown JE, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomized phase III trial for women with stage II/III breast cancer. In: 10th International Conference on Cancer-Induced Bone Disease; September 22-25, 2010; Sheffield, UK. P-23.
6. Allen MR. Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact. 2007;7(4):358-360.
7. DiFabio V. Osteonecrosis of jaw. In: ICD-9-CM Coordination and Maintenance Committee Meeting; September 28-29, 2006. Atlanta, GA: Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/data/icd9 /agendasep06.pdf. Accessed December 29, 2006.
8. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 2009;67(5 suppl):2-12.
9. Khosla S, Burr D, Cauley J, et al.; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(22):1479-1491. (Pubitemid 351229318)
10. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc. 2009;140(7):864-875.
11. Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg. 2008;66(7):1516-1517. (Pubitemid 351822447)
12. Woo SB, Mawardi H, Treister N. Comments on "Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification". Oral Oncol. 2009;45(8):740.
13. Bilezikian JP. Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med. 2006;355(22):2278-2281. (Pubitemid 44837776)
14. Black DM, Delmas PD, Eastell R, et al.; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. (Pubitemid 46698462)
15. Khan AA, Sándor GK, Dore E, et al.; Canadian Taskforce on Osteonecrosis of the Jaw. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009;36(3):478-490.
16. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826-836. (Pubitemid 351768801)
17. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29(8):1548-1558. (Pubitemid 47500128)
18. Lo JC, O'Ryan FS, Gordon NP, et al.; Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68(2):243-253.
19. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356-5362.
20. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol. 2007;4(12):711-721. (Pubitemid 350187006)
21. Wimalawansa SJ. Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf. 2008;7(4):491-512.
22. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bis-phosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst. 2007;99(13):1016-1024. (Pubitemid 47240676)
23. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther. 2006;28(2):151-173.
24. Body J-J. Treatment and prevention of bone metastases and myeloma bone disease. In: Rosen CJ, Compston JE, Lian JB, eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7th ed, Chapter 85. Hoboken, NJ: John Wiley & Sons, Inc; 2009:397-404.
25. Pazianas M, Epstein S, Zaidi M. Evaluating the antifracture efficacy of bisphosphonates. Rev Recent Clin Trials. 2009;4(2):122-130.
26. Mehrotra B. Bisphosphonates-role in cancer therapies. J Oral Maxillofac Surg. 2009;67(5 suppl):19-26.
27. Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res. 2010;25(3):606-616.
28. Pazianas M, Compston J, Huang CL-H. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010;25(1):2-10.
29. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733-759.
30. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581-589. (Pubitemid 28163009)
31. Dunford JE, Kwaasi AA, Rogers MJ, et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem. 2008;51(7):2187-2195. (Pubitemid 351503274)
32. Miller PD. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Nelson D, Rosen C, eds. Osteoporosis. 3rd ed. Burlington, MA: Elsevier; 2008:1725-1742.
33. Bisdas S, Chambron Pinho N, Smolarz A, Sader R, Vogl TJ, Mack MG. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol. 2008;63(1):71-77. (Pubitemid 350212865)
34. Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009;67(5 suppl):75-84.
35. O'Ryan FS, Khoury S, Liao W, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009;67(7):1363-1372.
36. Bedogni A, Blandamura S, Lokmic Z, et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(3):358-364.
37. Catalano L, Del Vecchio S, Petruzziello F, et al. Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. Ann Hematol. 2007;86(6):415-423. (Pubitemid 46630059)
38. Raje N, Woo SB, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14(8):2387-2395. (Pubitemid 351551072)
39. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol. 2006;35(4):236-243. (Pubitemid 44076879)
40. Bedogni A, Saia G, Ragazzo M, et al. Bisphosphonate-associated osteonecrosis can hide jaw metastases. Bone. 2007;41(6):942-945. (Pubitemid 350116746)
41. Frei M, Bornstein MM, Schaller B, Reichart PA, Weimann R, Iizuka T. Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case. J Oral Maxillofac Surg. 2010;68(4):863-867.
42. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44(9):857-869.
43. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008;66(5):987-994. (Pubitemid 351522818)
44. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35(3):155-160.
45. Burr DB, Allen MR. Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofac Res. 2009;12(3):221-228.
46. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104(10):1363-1374.
47. Follet H, Li J, Phipps RJ, Hui S, Condon K, Burr DB. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone. 2007;40:1172-1177. (Pubitemid 46386562)
48. Brown JE, Barrios CH, Diel IJ, et al. Incidence and outcomes of Osteonecrosis of the Jaw from an Integrated Analysis of Three Pivotal Randomized Double-Blind, Double-Dummy Phase 3 Trials Comparing Denosumab and Zoledronic Acid for Treatment of Bone Metastases in Advanced Cancer Patients or Myeloma. In: 10th International Conference on Cancer-Induced Bone Disease; September 22-25, 2010; Sheffield, UK. OC-15.
49. Johnston CC Jr, Lavy N, Lord T, Vellios F, Merritt AD, Deiss WP Jr. Osteopetrosis. A clinical, genetic, metabolic, and morphologic study of the dominantly inherited, benign form. Medicine (Baltimore). 1968;47(2):149-167.
50. Bénichou OD, Laredo JD, De Vernejoul MC. Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients. Bone. 2000;26(1):87-93.
51. Junquera L, Rodríguez-Recio C, Villarreal P, García- Consuegra L. Autosomal dominant osteopetrosis and maxillomandibular osteomyelitis. Am J Otolaryngol. 2005;26(4):275-278. (Pubitemid 40910034)
52. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw, Khosla S, Burr D, Cauley J, et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2008;66(6):1320-1321. (Pubitemid 351681930)
53. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302(3):1055-1061. (Pubitemid 34920226)
54. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62(22):6538-6544. (Pubitemid 35364119)
55. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9(8):2893-2897. (Pubitemid 36993246)
56. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005;63(5):682-689. (Pubitemid 40602707)
57. Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy [published online ahead of print May 13, 2010]. Breast Cancer Res Treat. 2010;122(1):189-191. doi: 10.1007/s10549-010-0933-9.
58. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122(1):181-188.
59. Estilo CL, Van Poznak CH, Wiliams T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist. 2008;13(8):911-920.
60. Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Investig. 2009;27(2):221-226.
61. Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 2009;76(3):209-211.
62. Kyrgidis A, Toulis KA. Denosumab-related osteonecrosis of the jaws [published online ahead of print March 20, 2010]. Osteoporos Int.
63. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone. 2009;44(1):4-10.
64. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol. 2001;59(2):193-202. (Pubitemid 32108550)
65. Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66(5):839-847. (Pubitemid 351522817)
66. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int. 2004;75(6):451-461. (Pubitemid 40174502)
67. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone. 2008;42(5):848-860.
68. Bune AJ, Hayman AR, Evans MJ, Cox TM. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disordered macrophage inflammatory responses and reduced clearance of the pathogen, Staphylococcus aureus. Immunology. 2001;102(1):103-113. (Pubitemid 32142520)
69. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953-64. (Pubitemid 41746764)
70. Hume DA, Loutit JF, Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: macrophages of bone and associated connective tissue. J Cell Sci. 1984;66:189-194. (Pubitemid 14051769)
71. Chang MK, Raggatt LJ, Alexander KA, et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol. 2008;181(2):1232-1244.
72. Barbeau J, Deslauriers N. Phenotypic and functional analysis of oral mucosal macrophages. Reg Immunol. 1989;2(5):285-293. PubMed PMID: 2534989.
73. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells [review]. Science. 2010;327(5966):656-661. PubMed PMID: 20133564; PubMed Central PMCID: PMC2887389.
74. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol. 2006;69(5):1624-1632.
75. Amin D, Cornell SA, Gustafson SK, et al. Bisphosphonates used for the treatment of bone disorders inhibit Squalene synthase and cholesterol biosynthesis. J Lipid Res. 1992;33(11):1657-1663.
76. Rogers MJ, Chilton KM, Coxon FP, et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res. 1996;11(10):1482-1491. (Pubitemid 26331003)
77. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008;66(4):767-775. (Pubitemid 351381805)
78. Kornak U, Kasper D, Bosl MR, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001;104(2):205-215. (Pubitemid 32174837)
79. Reichel H, Koeffler HP, Barbers R, Norman AW. Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J Clin Endocrinol Metab. 1987;65(6):1201-1209. (Pubitemid 18026859)
80. Bikle D. Vitamin D regulation of immune function: implications for bone loss during inflammation. Clin Rev Bone Miner Metab. 2009;7:301-309.
81. Hokugo A, Christensen R, Chung EM, et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res. 2010;25(6):1337-1349.
82. Anastasilakis AD, Toulis KA, Goulis DG, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res. 2009;41(10):721-729.
83. Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int. 2010;21:1963-1964 doi: 10.1007/s00198-009-1145-1.
84. Toulis KA, Anastasilakis AD. Erratum to: Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int. 2010;21:1965.
85. Seshasayee D, Wang H, Lee WP, et al. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response, J Biol Chem. 2004;279(29):30202-30209. (Pubitemid 38937945)
86. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA. 1993;90(8):3516-3520. (Pubitemid 23111397)
87. Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia. 2002;16(4):444-454. (Pubitemid 34449724)
88. Breuil V, Schmid-Antomarchi H, Schmid-Alliana A, Rezzonico R, Euller-Ziegler L, Rossi B. The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. FASEB J. 2003;17(12):1751-1753.
89. Koch FP, Walter C, Hansen T, Jäger E, Wagner W. Osteonecrosis of the jaw related to sunitinib [published online ahead of print April 18, 2010]. Oral Maxillofac Surg.
90. Mashkani B, Griffith R, Ashman LK. Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorg Med Chem. 2010;18(5):1789- 1797.
91. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884-896. (Pubitemid 350002890)
92. Grey A. Teriparatide for bone loss in the jaw. N Engl J Med. 2010;363(25):2458-2459.